SZodixStudyAcademic Library
ShelvesOpen access
Study · an open academic library·Metadata from OpenAlex (CC0)·Shelves·OpenAlex metadata, de-duplicated
An overview of pharmaceutical policy in four countries: France, Germany, the Netherlands and the United Kingdom
3 references·3 citing·28 second hop
An overview of pharmaceutical policy in four countries: France, Germany, the Netherlands and the United Kingdom (2005)An overview of pharmaceutical policy in f…Regulating Pharmaceuticals in Europe: Striving for Efficiency, Equity and Quality (2005)Regulating Pharmaceuticals in…Does It Pay to Work in the Public Sector? (1998)Does It Pay to Work in the Pu…Price regulation of drugs: Lessons from Germany (1996)Price regulation of drugs: Le…Comparing pharmaceutical pricing and reimbursement policies in Croatia to the European Union Member States (2011)Comparing pharmaceutical pric…Pharmaceutical policies: effects of financial incentives for prescribers (2007)Pharmaceutical policies: effe…Impact of Cross-Reference Pricing on Pharmaceutical Prices (2006)Impact of Cross-Reference Pri…Consumer Demand. A New Approach. (1972)Consumer Demand: A New Approach. (1975)What Happened to Americans' Support for the Clinton Health Plan? (1995)Review of the Literature on Reference Pricing (1999)Impact of reference-based pricing of nitrates on the use and costs of anti-anginal drugs. (2001)Reference Pricing of Pharmaceuticals for Medicare: Evidence from Germany, the Netherlands and New Zealand (2003)Cross-national price differences for pharmaceuticals: how large, and why? (2000)Review of the literature on reference pricing (2000)Regulating pharmaceuticals in Europe : striving for efficiency, equity and quality (2004)A systematic review of coverage decision-making on health technologies—Evidence from the real world (2012)Reference Pricing as a Deterrent to Entry: Evidence from the European Pharmaceutical Market (2020)The impact of price regulation on the launch delay of new drugs—evidence from twenty‐five major markets in the 1990s (2004)Medicine prices, availability, and affordability in 36 developing and middle-income countries: a secondary analysis (2008)THE WORLD MEDICINES SITUATION 2011 (2011)Analysis of Medicine Prices in New Zealand and 16 European Countries (2015)National Bureau of Economic Research 1961 (1962)British Unions in Decline: Determinants of the 1980s Fall in Union Recognition (1995)Estimating the Effects of Unions on Wage Inequality in a Panel Data Model with Comparative Advantage and Nonrandom Selection (1998)Assessing the Incidence and Wage Effects of Overskilling in the Australian Labour Market (2009)The Public-Private Pay Gap: A Robust Quantile Approach (2011)Teacher Value Added in a Low-Income Country (2020)Mass media interventions: effects on health services utilisation (2002)INTERRUPTED TIME SERIES DESIGNS IN HEALTH TECHNOLOGY ASSESSMENT: LESSONS FROM TWO SYSTEMATIC REVIEWS OF BEHAVIOR CHANGE STRATEGIES (2003)Paying For Quality: Providers’ Incentives For Quality Improvement (2004)Quality use of medicines within universal health coverage: challenges and opportunities (2014)Competition in off-patent drug markets: Issues, regulation and evidence (2008)Pharmaceutical policies in European countries in response to the global financial crisis (2011)Pharmaceutical policies: effects of financial incentives for prescribers (2015)
this work references cited by second hop

References

  • 1998Does It Pay to Work in the Public Sector?175 cited
  • 2005Regulating Pharmaceuticals in Europe: Striving for Efficiency, Equity and Quality155 cited
  • 1996Price regulation of drugs: Lessons from Germany73 cited

Cited by

  • 2006Impact of Cross-Reference Pricing on Pharmaceutical Prices63 cited
  • 2007Pharmaceutical policies: effects of financial incentives for prescribers60 cited
  • 2011Comparing pharmaceutical pricing and reimbursement policies in Croatia to the European Union Member States58 cited

Only edges whose both ends are imported exist here. Widen the year window, or show the whole map. Back to the work